CD4 and tuberculosis: For example, early combination antiretroviral therapy (cART) could be considered for high-risk patients even though their CD4+ level ≥50 cells/mm3 as the cART has been shown to reduce up to 68% TB-related deaths in TB/HIV co-infected patients [18].